Reading ACHV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACHV free→Reading ACHV? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track ACHV free→QuarterlyIQ Insights · ACHV
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. Appointment of Board Members On May 29, 2026, the Board of Directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”) appointed Jeff Farrow and Reid Waldman, M.D. (together, the “Incoming Directors”), as directors, effective as of such date. Mr. Marrow has also been appointed to the Nominating and Governance Committee of the Board as a…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Appointment of Board Member In connection with the previously reported private placement (the “Private Placement”) of the Company’s securities, and pursuant to the designation right granted to Frazier Life Sciences, on May 11, 2026, the Company’s board of directors (the “Board”) appointed Christopher Martin to serve as a director of the Company, e…
of Form 8-K, is hereby incorporated by reference herein. Based in part upon the representations of the Investors in the Securities Purchase Agreement, the offering and sale of the Securities was made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and corresponding provisions of state securities or “blue sky” laws. The Securities have not been registered under the Securities Act or any state securities laws and may not…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . Departure of Chief Executive Officer In connection with the Private Placement, on April 15, 2026, Richard Stewart, the Company’s Chief Executive Officer and a director, informed the Company’s Board of Directors (the “Board”) of his intention to step down from his position as the Company’s Chief Executive Officer, President and “principal executive…
Regulation FD Disclosure . On April 16, 2026, the Company issued a press release announcing the Private Placement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Item 7.01, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that sect…
Entry into a Material Definitive Agreement . Securities Purchase Agreement On April 15, 2026, Achieve Life Sciences, Inc. (the “Company”), entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional and accredited investors (the “Investors”), pursuant to which the Company agreed to sell and issue to the Investors in a private placement (the “Private Placement”) an aggregate of (i) 49,418,069 shares (the “Shares”) of the Company’s common stock,…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 11, 2025, Achieve Life Sciences, Inc. (the “Company”) previously announced that Dr. Cindy Jacobs had informed the Company’s board of directors that she had elected to resign from her role as the Company’s Chief Medical Officer and President, effective as of October 6, 2025 (the “Separation Date”). In connection with her resignation, on…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 5, 2025, Dr. Cindy Jacobs informed the board of directors (the “Board”) of Achieve Life Sciences, Inc. (the “Company”), that she has elected to resign from her role as the Company’s Chief Medical Officer and President, effective as of October 6, 2025. The Company is in the process of negotiating the terms of a consulting agreement with…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
Entry into a Material Definitive Agreement. On June 26, 2025, Achieve Life Sciences, Inc. (“Achieve”) entered into an underwriting agreement (the “Underwriting Agreement”) with Citizens JMP Securities, LLC and Raymond James & Associates, Inc., as representatives of the underwriters named therein (the “Underwriters”), pursuant to which Achieve agreed to issue and sell to the Underwriters (i) 15,000,000 shares of its common stock (the “Shares”) and (ii) accompanying common warrants (the “Accomp…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
of this Form 8-K and Exhibit 99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. ________________________ SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.